21 December 2022: A formulated product mainly containing Aker BioMarine's
Superba krill oil was today approved by the Ministry of Food and Drug Safety
(MFDS) in South Korea as an individually approved product with joint health
claims.
In late 2020, the governmental bodies in South Korea tightened the regulation on
the krill oil category, effectively closing all sales of krill oil products.
With the new regulation in place, all krill oil products require approval as
Health Functional Food to resume sales activities in the country.
The product is a formulation including krill oil with anti-inflammatory,
antioxidant and joint tissue protection effects, and its scientific efficacy on
joint health has been proven through animal and human application tests.
Aker BioMarine and its local partner also have Health Functional Food
applications in process for other claims for Superba kill oil in South Korea.
The company expects approvals of these claims as we move into 2023.
For further information, please contact
Carl Christian Bachke, Investor Relations
Mobile: +47 909 808 48
Email: carl.bachke@akerbiomarine.com
This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 the Norwegian Securities Trading Act. This stock exchange
announcement was published by Carl Christian Bachke, Investor Relations, on 21
December 2022, at 14:19 CET.
About Aker BioMarine
Aker BioMarine is a leading biotech innovator and Antarctic krill-harvesting
company developing krill-derived products for pharma, consumer health and
wellness as well as animal nutrition. The company has a strong position in its
industry and is the world's leading supplier of krill, the natural, powerful and
health promoting source of nutrients from the pristine waters of Antarctica.
Aker BioMarine is listed on Oslo Stock Exchange (AKBM). More information is
available at www.akerbiomarine.com.